6-(甲基硫代)烟酸甲酯 | 74470-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(甲基硫代)烟酸甲酯
• 英文名称: 2-methylthiopyridine-5-carboxylic acid methyl ester
• 英文别名: methyl 6-(methylsulfanyl)nicotinate；methyl 6-methylthiopyridine-3-carboxylate；methyl 6-(methylthio)nicotinate；methyl 6-methylsulfanylpyridine-3-carboxylate
• CAS: 74470-40-9
• 化学式: C₈H₉NO₂S
• mdl: MFCD01928252
• 分子量: 183.231
• InChiKey: KMYTWSGXEHSNRY-UHFFFAOYSA-N

物化性质

• 熔点：
  54 °C
• 沸点：
  290.1±25.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(甲基硫代)烟酸甲酯 生成 6-疏基吡啶-3-羧酸甲酯
  参考文献：
  名称：

  The methyl group as a protectinq group for arylthiols: a mild and efficient method for the conversion of methyl aryl sulfides to arylthiols

  摘要：

  DOI：

  10.1016/s0040-4039(01)90033-4
• 作为产物：
  描述：

  6-氯烟酸 以 甲醇 、 正己烷 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 28.0h， 生成 6-(甲基硫代)烟酸甲酯
  参考文献：
  名称：

  [EN] MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR MUSCARINIQUE M1

  摘要：

  公开号：

  WO2018042362A9

文献信息

• CARBINOL DERIVATIVES HAVING CYCLIC LINKER
  申请人：Yamaguchi Yuki

  公开号：US20100048610A1

  公开（公告）日：2010-02-25

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。【解决手段】以下一般式（I）所表示的羟甲基化合物或其盐，或其溶剂化合物。
• [EN] HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] COMPPOSÉS DE PHÉNANTHROLINONE FUSIONNÉS HÉTÉROCYCLIQUES UTILES COMME MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1
  申请人：MERCK SHARP & DOHME

  公开号：WO2011159553A1

  公开（公告）日：2011-12-22

  The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的杂环融合苯并吡喃酮化合物，这些化合物是M1受体阳性变构调节剂，对治疗M1受体参与的疾病如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍具有用处。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗由M1受体介导的疾病中的用途。
• Synthesis of pyridone and pyridine rings by [4+2] hetero-cyclocondensation
  作者：Aélig Robin、Karine Julienne、Jean Claude Meslin、David Deniaud

  DOI：10.1016/j.tetlet.2004.10.142

  日期：2004.12

  Substituted pyridones and pyridines have been synthesised efficiently by employing iminium salt as a key precursor. These compounds were prepared using tandem [4+2] cycloaddition/deamination between azabutadiene and dienophiles.

  通过使用亚胺盐作为关键前体，可以有效地合成取代的吡啶酮和吡啶。这些化合物是使用azabutadiene和dienophiles之间的串联[4 + 2]环加成/脱氨基反应制备的。
• Carbinol derivatives having cyclic linker
  申请人：Kowa Company, Ltd.

  公开号：US08153634B2

  公开（公告）日：2012-04-10

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  【目标】提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化、动脉硬化（如糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、与脂质相关的疾病、由炎性细胞因子引起的炎症性疾病、过敏性皮肤病、糖尿病或阿尔茨海默病的治疗剂。 【解决方法】以下通式（I）所表示的羟基甲基化合物或其盐，或其溶剂。
• Isoindolone M1 receptor positive allosteric modulators
  申请人：Beshore Douglas C.

  公开号：US08697690B2

  公开（公告）日：2014-04-15

  The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的异吲哚酮化合物，它们是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的用途。